|
|
|
|
| LEADER |
03269nam a22005055i 4500 |
| 001 |
978-3-319-11514-6 |
| 003 |
DE-He213 |
| 005 |
20151204150348.0 |
| 007 |
cr nn 008mamaa |
| 008 |
141128s2015 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783319115146
|9 978-3-319-11514-6
|
| 024 |
7 |
|
|a 10.1007/978-3-319-11514-6
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a RM1-950
|
| 072 |
|
7 |
|a MMG
|2 bicssc
|
| 072 |
|
7 |
|a MED071000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 615
|2 23
|
| 245 |
1 |
0 |
|a Drug Treatment of Sleep Disorders
|h [electronic resource] /
|c edited by Antonio Guglietta.
|
| 264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2015.
|
| 300 |
|
|
|a VIII, 297 p. 23 illus., 14 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Milestones in Drug Therapy,
|x 2296-6056
|
| 505 |
0 |
|
|a An overview of sleep physiology and sleep regulation -- Neuronal networks regulating sleep and arousal: effect of drugs -- Classification of sleep disorders -- Development of new therapeutical agents for treatment of insomnia and other sleep disorders -- Low dose doxepin for insomnia -- Lorediplon: a new GABAa modulator drug for treatment of insomnia -- Zolpidem sublingual formulations -- Eszopiclone: review and clinical applications in chronic and co-morbid insomnia -- Orexin/hypocretin antagonists in insomnia: from bench to clinic -- Modafinil and armodafinil -- Sodium oxybate (Xyrem®): a new and effective treatment for narcolepsy with cataplexy -- Cell therapy to treat narcolepsy -- Tasimelteon -- The past, present and future of drug development and treatment in sleep disorders.
|
| 520 |
|
|
|a Following reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Neurosciences.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
|
0 |
|a Psychopharmacology.
|
| 650 |
|
0 |
|a Pharmacotherapy.
|
| 650 |
1 |
4 |
|a Biomedicine.
|
| 650 |
2 |
4 |
|a Pharmacology/Toxicology.
|
| 650 |
2 |
4 |
|a Neurosciences.
|
| 650 |
2 |
4 |
|a Pharmacotherapy.
|
| 650 |
2 |
4 |
|a Psychopharmacology.
|
| 700 |
1 |
|
|a Guglietta, Antonio.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319115139
|
| 830 |
|
0 |
|a Milestones in Drug Therapy,
|x 2296-6056
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-3-319-11514-6
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 950 |
|
|
|a Biomedical and Life Sciences (Springer-11642)
|
